In a holding that could significantly broaden the antitrust inquiry in the context of the Hatch-Waxman regulatory scheme, on February 13, 2020, the U.S. Court of Appeals for the First Circuit issued an opinion that may have...more
2/26/2020
/ Antitrust Litigation ,
Antitrust Provisions ,
Antitrust Violations ,
Appeals ,
Food and Drug Administration (FDA) ,
Generic Drugs ,
Hatch-Waxman ,
Intellectual Property Protection ,
Investigational New Drug Application (IND) ,
Medical Devices ,
Orange Book ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Sanofi-Aventis ,
Section 2 ,
Sherman Act